Factors Affecting Postoperative Recurrence in Patients with Pathological Stage IB Non-small-cell Lung Cancer

目的.非小細胞肺癌患者は術後補助化学療法が有効であると示されつつある.IB期患者で再発に影響を与える因子を解析し,どのような患者について化学療法を省くことができるかを検討した.対象と方法.縦隔リンパ節郭清を行い完全切除した病理病期IB期非小細胞肺癌患者225名を対象とした.年齢,性別,喫煙歴,術前CEA値,左右,術式,腫瘍サイズ,組織型,分化度,胸膜浸潤の有無の臨床病理学的因子から再発に影響を与える因子を解析した.結果.5年,10年全生存割合は,各々73%,57%であった.再発は87名(39%)にみられた.5年,10年無再発生存率は,各々63%,51%であった.単変量解析では腫瘍サイズが有意な因子で,4 cm未満,4 cm以上の5年無再発生存率は各々70%,57%であった(P=0.018).組織型では腺変扁平上皮癌が扁平上皮癌,大細胞癌と比べて有意に予後不良であった.多変量解析では腫瘍サイズが有意な予後因子であった.結論.肺癌術後IB期患者で再発がより少ない要因は,腫瘍サイズが4 cm未満でかつ,大細胞癌または扁平上皮癌であった.この患者群に対しては化学療法を省ける可能性がある.

[1]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[2]  G. Scagliotti,et al.  Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Sugarbaker,et al.  Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Giannarelli,et al.  Treatment of resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[5]  H. Wada,et al.  Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[7]  R. Schilsky,et al.  Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[9]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[10]  G. Giaccone,et al.  Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. , 2003, Journal of the National Cancer Institute.

[11]  M. Oda,et al.  Proposals regarding some deficiencies in the new international staging system for non-small cell lung cancer. , 1991, Japanese journal of clinical oncology.

[12]  M. Noguchi,et al.  Clinicopathologic characteristics of adenosquamous carcinoma of the lung , 1991, Cancer.

[13]  M. Haniuda,et al.  Assessment of Neoplasm Staging for Pathologic Stage I Non-small Cell Lung Cancer Using Postoperative Results. , 2001 .